The stock of Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) increased by $0.24 on Friday to finish at $7.74, up 3.20 percent. The last five days have seen an average of 2,056,520 shares of common stock traded. 10 times new highs were reached in the current year, with a fall of -$7.06. The average number of shares traded over the last 20 days was 1,098,515, while the average volume over the last 50 days totaled 1,126,432.
ARQT stock dropped -22.60% since last month. On 08/21/23, the company’s shares reached a one-month low of $6.39. The stock touched a high of $27.40 on 03/01/23, after rallying from a low of $6.39 in 52 weeks. The price of ARQT stock has declined by -47.70% or -$7.06 this year, reaching a new high 10 times. Still, the stock price is down -71.75% from the 52-week high.
Insider Transactions
ARQT stock investors should be aware that Arcutis Biotherapeutics Inc. (ARQT) stock had its last reported insider trading activity 7 days ago on Aug 21. On Aug 21, Burnett Patrick sold 1,605 shares at $7.04 each. This transaction resulted in the insider making $11,302. On May 31, Matsuda Masaru sold 1,830 shares at a price of US$7.80. After the transaction, the insider now owns 42,146 shares. Director Welgus Howard G. had earlier sold 8,500 shares on Apr 17 for $13.97 a share. The transaction was completed for $118,728.
Valuation Metrics
Beta for the stock is 0.71. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 39.52, the price-to-book (PB) ratio of 5.91.
Financial Health
For the three months ended June 29, Arcutis Biotherapeutics Inc.’s quick ratio was 8.10, while its current ratio was 8.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 2.48, and the total debt to equity ratio is 2.48. As far as profitability goes, gross margin for the trailing twelve months is 80.20% percent. Based on annual data, it had gross profit of $2.93 million and revenue of $3.69 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ARQT’s return on assets (ROA) during the last 12 months has been -79.80%. There was a -74.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -188.90%.
Earnings Surprise
According to Arcutis Biotherapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $5.19 million, while revenues rose by 100.0% to $2.78 million. It was predicted that Arcutis Biotherapeutics Inc.’s quarterly earnings would be -$1.16, but it ended up being -$1.25, beating the consensus by 7.20%. EBITDA was -$68.2 million for the quarter. At the end of Arcutis Biotherapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 240.18 million, while its total debt was $204.22 million. Equity owned by shareholders amounts to $61.65 million.
Technical Picture
Here’s a quick look at Arcutis Biotherapeutics Inc.’s (ARQT) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 32.10%, suggesting the stock is Neutral, with a 28.49% historical volatility rate.
The stochastic %K and %D were 26.39% and 24.66% respectively, while the average true range (ATR) was 0.61. Based on the 14-day stochastic reading of 29.79%, the RSI (14) reading is 34.35%. On the 9-day MACD Oscillator, the stock is at -0.21, and the 14-day reading is at -0.72.
Analyst Ratings
In its analyst report released on September 07, 2022, Needham began covering Arcutis Biotherapeutics Inc. (NASDAQ: ARQT). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Arcutis Biotherapeutics Inc. (ARQT) an Buy rating. ARQT is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 8 others recommend it as a buy.
What is ARQT’s price target for the next 12 months?
The current consensus forecast for the stock is between $22.00 and $57.00, with a median target price of $44.50. In analyzing these forecasts, the average price target given by analysts for Arcutis Biotherapeutics Inc. (ARQT) is $41.88.
